HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Issues Final Lead-In-Lipstick Report, Postpones Decision On Cosmetic Lead Limits

This article was originally published in The Rose Sheet

Executive Summary

FDA’s expanded survey of lead levels in lipstick examined 400 products on the market, finding an average amount of 1.11 ppm, comparable with its initial test of 20 lipsticks, which averaged 1.07 ppm lead content.

You may also be interested in...

FDA’s 10ppm Cosmetic Lead Limit Criticized, Including By Industry Player

FDA’s draft guidance setting a 10ppm limit on trace lead in cosmetic products is not protective enough, according to stakeholders, including Beautycounter, which bills itself as “a company devoted to progress.” Commenter recommendations range from lowering the ceiling to banning lead-contaminated products outright.

FDA Issues Second Warning This Year For Bentonite Clay Lead, Claims

Following a January consumer alert and March warning letter to Alikay Naturals for high lead levels, unapproved drug claims and mislabeling issues related to Bentonite Me Baby, FDA comes down on Best Bentonite for similar issues in a warning letter published Nov. 22.

FDA Going Through Enforcement Toolkit To Address Bentonite Me Baby

FDA lab analysis found lead in Alikay Naturals' Bentonite Me Baby clay at a level of 37.5 ppm, according to a March 16 warning letter citing the purported cosmetic as an unapproved and misbranded drug. The agency cautioned consumers about the product in January and seems to be urging the company to recall it, which may draw attention to the authority FDA currently lacks under federal food, drug and cosmetic law.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts